TSE:HBP Helix BioPharma (HBP) Stock Price, News & Analysis → “The Stock Market’s Bull Run is Far from Over” -Barrons (From Vertical Research Advisory) (Ad) Free HBP Stock Alerts C$0.18 0.00 (0.00%) (As of 03/28/2024 04:30 PM ET) Add Compare Share Share Today's RangeC$0.18▼C$0.1850-Day RangeC$0.17▼C$0.2252-Week RangeC$0.15▼C$0.26Volume14,017 shsAverage Volume16,812 shsMarket CapitalizationC$39.00 millionP/E RatioN/ADividend Yield1.50%Price TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsStock AnalysisChartCompetitorsEarnings Get Helix BioPharma alerts: Email Address Ad Vertical Research Advisory“The Stock Market’s Bull Run is Far from Over” -BarronsBarron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!Click here for all the details now… About Helix BioPharma Stock (TSE:HBP)Helix BioPharma Corp. operates as an immune-oncology company in Canada. It is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with University Hospital Tuebingen to assess the therapeutic response of L-DOS47 in cancer models expressing CEACAM6, with advanced preclinical metabolic imaging. The company is headquartered in Toronto, Canada.Read More HBP Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart HBP Stock News HeadlinesMarch 28, 2024 | ca.finance.yahoo.comCanadian Investment Regulatory Organization Trading Halt - HBPMarch 23, 2024 | americanbankingnews.comHelix BioPharma (TSE:HBP) Stock Passes Above 50 Day Moving Average of $0.19March 29, 2024 | Behind the Markets (Ad)Central Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.October 10, 2023 | finance.yahoo.comHelix Biopharma Announces Upcoming Poster Presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsAugust 22, 2023 | stockhouse.comHelix BioPharma Corp. Announces Closing of Private Placement of CAD $3 Million and Board ChangesJune 14, 2023 | msn.comHelix Biopharma GAAP EPS of -C$0.01June 14, 2023 | finance.yahoo.comHelix BioPharma Corp. Announces Fiscal 2023 Third Quarter ResultsNovember 1, 2022 | proactiveinvestors.comHelix BioPharma advances clinical development of lead candidate L-DOS47, but manages to decrease R&D expenses in 2022 fiscal yearMarch 29, 2024 | Behind the Markets (Ad)Central Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.November 1, 2022 | finance.yahoo.comHELIX BIOPHARMA CORP. Announces Fiscal 2022 Year-End ResultsSeptember 2, 2022 | proactiveinvestors.comHelix BioPharma Corp names Dr Gabrielle Siegers as its head of research and developmentSeptember 2, 2022 | proactiveinvestors.comHelix BioPharma names Dr Gabrielle Siegers as head of research and developmentSeptember 1, 2022 | finance.yahoo.comHelix Biopharma Corp. Appoints Gabrielle M Siegers as the Head of Research & DevelopmentAugust 30, 2022 | finance.yahoo.comHelix Biopharma Corp. Announces Conclusion of Funding Agreement with Lind Global Macro Fund LPJune 14, 2022 | finance.yahoo.comHELIX BIOPHARMA Corp. Announces Fiscal 2022 Third Quarter ResultsJune 3, 2022 | finance.yahoo.comHelix Biopharma Corp. Announces Closure of Early Warrant Exercise Incentive Program | Raises Aggregate $3.21 MillionMay 17, 2022 | finance.yahoo.comInsiders may be rethinking their CA$3.0m Helix BioPharma Corp. (TSE:HBP) investment now that the company has lost CA$5.0m in valueApril 22, 2022 | finance.yahoo.comJerzy Wilczewski Announces Acquisition of Common Shares of Helix Biopharma Corp.April 18, 2022 | finanznachrichten.deHelix BioPharma Corp.: Helix Biopharma Corp. Announces Appointment of Permanent CEO and Independent Board MembersApril 18, 2022 | finance.yahoo.comHelix Biopharma Corp. Announces Appointment of Permanent CEO and Independent Board MembersApril 7, 2022 | finanznachrichten.deHelix BioPharma Corp.: Helix Announces Board ResignationMarch 22, 2022 | finanznachrichten.deHelix BioPharma Corp.: Helix Biopharma Corp. Announces Management and Board ChangesMarch 22, 2022 | finance.yahoo.comHelix Biopharma Corp. Announces Management and Board ChangesMarch 16, 2022 | finanznachrichten.deHelix BioPharma Corp.: Helix Biopharma Corp. Announces Fiscal 2022 Second Quarter ResultsMarch 16, 2022 | proactiveinvestors.comHelix BioPharma announces sudden passing of interim CEO Slawomir MajewskiMarch 11, 2022 | apnews.comHelix Biopharma Corp. Closes Private Placement and Announces Early Warrant Exercise Incentive Program and Extension of Warrant Exercise PeriodMarch 11, 2022 | finance.yahoo.comHelix Biopharma Corp. Closes Private Placement and Announces Early Warrant Exercise Incentive Program and Extension of Warrant Exercise PeriodSee More Headlines Receive HBP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Helix BioPharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today3/28/2024Next Earnings (Estimated)4/03/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeTSE SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolTSE:HBP CUSIPN/A CIKN/A Webwww.helixbiopharma.com Phone+1-416-9253232FaxN/AEmployees9Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)C($0.03) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeC$-5,940,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-111.88% Debt Debt-to-Equity Ratio773.67 Current Ratio1.46 Quick Ratio1.04 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares216,670,000Free FloatN/AMarket CapC$39.00 million OptionableNot Optionable Beta-0.71 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesMr. Jacek AntasChairman & CEOMr. Praveen Kumar Varshney F.C.A. (Age 58)FCA, FCPA, LLB, CFO & Corporate Secretary Dr. Gabrielle M. Siegers M.A.Ph.D., Head of R&DDr. Srikanth SolaChief Strategy OfficerDr. Christof BoehlerChief Business Development OfficerKey CompetitorsIBEX TechnologiesCVE:IBTAptose BiosciencesTSE:APSDevonian Health GroupCVE:GSDCovalon TechnologiesCVE:COVSmall PharmaCVE:DMTView All Competitors HBP Stock Analysis - Frequently Asked Questions How have HBP shares performed in 2024? Helix BioPharma's stock was trading at C$0.21 at the beginning of 2024. Since then, HBP stock has decreased by 14.3% and is now trading at C$0.18. View the best growth stocks for 2024 here. When is Helix BioPharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 3rd 2024. View our HBP earnings forecast. What other stocks do shareholders of Helix BioPharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Helix BioPharma investors own include Lakeland Industries (LAKE), Liquidia (LQDA), Ovintiv (OVV), SIG (SHI), Green Organic Dutchman (TGOD), Zynerba Pharmaceuticals (ZYNE), American Airlines Group (AAL), Aurora Cannabis (ACB), Apollo Investment (AINV) and Aphria (APHA). How do I buy shares of Helix BioPharma? Shares of HBP stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. This page (TSE:HBP) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders Alliance“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyOnly a fool would buy Nvidia today… Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Helix BioPharma Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.